GlassScriptPhysician profile
Parvin Afshar
NPI 1437247335
$10,341.25
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,514 · 2020: $2,057 · 2021: $1,889 · 2022: $891 · 2023: $536 · 2024: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,506.79 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $1,222.52 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $1,171.17 | 2019-2023 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $831.12 | 2019-2023 | Invega, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $755.49 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $633.86 | 2019-2024 | Aristada, Lybalvi |
| Allergan, INC. | $617.67 | 2019 | |
| Abbvie INC. | $590.12 | 2021-2024 | Vraylar |
| Lundbeck LLC | $552.39 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $404.94 | 2021-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $329.89 | 2020-2023 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $270.74 | 2019-2022 | |
| Indivior INC. | $253.78 | 2019-2023 | Perseris |
| Bausch Health US, LLC | $169.65 | 2019-2021 | |
| Neos Therapeutics, LP | $158.57 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $157.63 | 2019 | |
| Noven Therapeutics, LLC | $125.83 | 2020-2021 | |
| Axsome Therapeutics, INC. | $100.71 | 2022-2023 | Auvelity |
| Acadia Pharmaceuticals INC | $94.54 | 2019-2021 | |
| Adlon Therapeutics L.P. | $75.03 | 2019-2021 | |
| Eisai INC. | $74.29 | 2020-2021 | |
| Corium, LLC | $66.99 | 2021-2022 | |
| Livanova USA, INC. | $46.67 | 2020-2021 | |
| Almatica Pharma LLC | $33.96 | 2023 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $32.21 | 2023 | Quviviq |
| Shire North American Group INC | $22.74 | 2019 | |
| Merck Sharp & Dohme LLC | $17.70 | 2021 | |
| Biogen, INC. | $16.45 | 2021 | |
| Brainsway USA INC | $7.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvin Afshar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.